Las Vegas—As medication experts and some of the most accessible members of the healthcare team, pharmacists are well positioned to support the continued adoption of biosimilars.
However, several clinical, operational and financial challenges—as well as misperceptions—need to be overcome for biosimilars to reach their full potential, Sonia Oskouei, PharmD, vice president, Biosimilars, for Cardinal Health, said during a presentation at the AXS22/Asembia Specialty